Application of dehydroabietin amine and squaramide compounds in the development of anti-tumor drugs and pharmaceutical compositions thereof

By developing dehydrogenated rosin amine samide derivatives, the problems of limited effects and complex preparation of existing anti-tumor drugs have been solved, effective inhibition of various tumor cells and significant inhibition of tumor growth are achieved, and new anti-tumors are provided Basics of drug development.

CN114712339BActive Publication Date: 2024-11-26GUANGXI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210267376.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-15
Publication Date
2024-11-26
Estimated Expiration
2042-03-15

AI Technical Summary

Technical Problem

Existing anti-tumor drugs have limited effects in inhibiting tumor cell growth and inducing apoptosis, and the preparation process is complex and the raw materials are expensive, making it difficult to widely use.

Method used

A new class of dehydrogenated rosinamine samide derivatives were developed to prepare fatty amine-substituted and samide-substituted compounds by synthesizing routes 1 and 2, demonstrating the inhibitory activity of a variety of tumor cells and through in vitro and in vivo Experimental verification of its anti-tumor effect.

Benefits of technology

Compound 2 shows that low concentration can effectively inhibit tumor cell growth and induce G1 phase block and apoptosis. In vivo experiments have shown that tumor growth is significantly inhibited, the preparation process is simple, the raw materials are cheap, and it has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114712339B_ABST
    Figure CN114712339B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of anti-tumor drugs, the application of dehydroabietin amine and squaramide compounds in the development of anti-tumor drugs and pharmaceutical compositions thereof. Through in vitro anti-tumor activity experimental studies, the compounds of the present invention all show different degrees of anti-tumor cell proliferation activity, and can strongly inhibit tumor cell growth at low concentrations and induce tumor cells to produce G 1 The compounds of the present invention can significantly inhibit tumor growth in tumor-bearing mice. The preparation process of such compounds is simple and easy, the raw materials are cheap, easy to obtain and can be made into pharmaceutical compositions with conventional pharmaceutical carriers. Such novel dehydroabietin amine and squaramide structures provide a basis for the development of new anti-tumor drugs and have good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of anti-tumor drug development, and specifically relates to the application of a dehydroabietin amine and squaramide compound in the development of anti-tumor drugs. Background Art

[0002] In recent years, natural products have been widely studied due to their significant antitumor, antibacterial and antifungal activities. Among them, rosin has received increasing attention due to its excellent biological activity. Dehydroabietinamine is one of the important modified products of rosin. The antitumor, antibacterial, antifungal, cytotoxic and antiparasitic activities of dehydroabietinamine derivatives have been a research hotspot in the field of forest chemistry in recent years.

[0003] In addition, squaric acid is an interesting small molecule with a nearly perfect square shape, and its analogs have a variety of biological activities due to their important hydrogen bond donors and acceptors. Squaramides have been widely studied in the field of asymmetric organic catalysis due to their ability to selectively bind hydrogen bonds. In addition to their applications in catalysis, the ability of squaramides as molecular recognition receptors is currently being explored in medicinal chemistry. This project intends to synthesize a series of dehydroabietinamine derivatives by combining dehydroabietinamine with squaramides and evaluate their biological activities, providing available candidate compounds for new drug discovery. Summary of the invention

[0004] The present invention relates to the field of anti-tumor drugs. Dehydroabietin amine and squaramide derivatives are a new type of diterpenoid structure. Through in vitro anti-tumor activity experimental studies, the compounds of the present invention all show different degrees of anti-tumor cell proliferation activity, and can strongly inhibit tumor cell growth at low concentrations, induce tumor cells to produce G1 phase arrest, and induce tumor cell apoptosis. In vivo anti-tumor experimental studies have shown that the compounds of the present invention can significantly inhibit tumor growth in tumor-bearing mice. The preparation process of this type of compound is simple and easy, and the raw materials are low in price and easy to obtain; therefore, this type of new dehydroabietin amine and squaramide structure provides a basis for the development of new anti-tumor drugs and has good clinical application prospects.

[0005] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0006] The application of dehydroabietin amine and squaramide derivatives in the preparation of anti-tumor drugs, the preparation route and structure of the dehydroabietin amine and squaramide compound are as follows:

[0007] Route 1:

[0008]

[0009] Route 2:

[0010]

[0011] Note: Dehydroabietin amine and squaramide substituted with fatty amine are synthesized by route 1, and dehydroabietin amine and squaramide substituted with squaramide are synthesized by route 2.

[0012] Evaluation of the antitumor activity of compounds in vitro

[0013] Test tumor cells: human liver cancer cell HepG2, human lung cancer cell A549, human prostate cancer cell DU145, human colon cancer cell HT29, human colon cancer cell HCT15.

[0014] Cell culture: DMEM, DMEM-F12, MEM, RPMI 1640 and McCoys5A medium, 10% fetal bovine serum and 1% penicillin-streptomycin were used as culture medium. The cultured cell lines were placed at 37°C and 5% CO2 saturated humidity for routine culture and passage. All experiments used cells in the logarithmic growth phase.

[0015] In vitro antitumor activity evaluation (MTT method):

[0016] The above tumor cells were plated on 96-well plates, and after the monolayer was grown in a 37°C, 5% CO2 incubator, the cell culture medium was discarded, and the cell maintenance medium containing different concentrations of the test compound was added to continue the culture. The cells without drug action were used as blank controls. Each group had 8 replicate wells and continued to culture for 48 hours. The cell status was visually observed and recorded under a microscope. 10 μL of MTT (5 mg / mL) was added to each well and continued to culture for 4 hours. The supernatant was discarded, and 100 μL of DMSO was added to each well. The cells were incubated at 37°C for 10 minutes, and the absorbance at a wavelength of 490 or 570 nm was detected by an enzyme marker. The average inhibition rate was calculated according to the following formula:

[0017] Inhibition rate = (average OD value of the control group - average OD value of the drug group) / average OD value of the control group) × 100%.

[0018] The test results showed that the eleven dehydroabietin amine and squaramide compounds prepared showed excellent inhibitory activity against the tested tumor cells, and their half inhibitory concentration (IC 50 The specific results are shown in Table 1 below, among which compound 2 (R = (1S, 2S)-2-NH2-cyclohexyl) has the best anti-tumor effect.

[0019] Table 1 Inhibitory activity of dehydroabietin amine and amide compounds on tumor cells (IC 50 )

[0020]

[0021] The applicant further implemented an experiment on compound 2 inducing tumor cell apoptosis, and the experimental conditions were as follows: HT29 cells in the logarithmic growth phase were plated on a 6-well plate, and after the monolayer was fully grown, cell maintenance medium containing 2.5 μM, 10 μM, and 15 μM of compound 2 was added for incubation, and a cell control without drug treatment was set. After 24 hours, the cells were collected and apoptosis was detected on a flow cytometer using the Annexin-FITC / PI apoptosis detection kit.

[0022] The experimental results are as follows Figure 1 The results show that compound 2 can strongly induce apoptosis of the above tested tumor cells.

[0023] The object of the present invention is to provide the use of dehydroabietin amine and squaramide derivatives in the preparation of anti-tumor drugs, and the structures include but are not limited to 1-11.

[0024] Furthermore, the drug is for treating, including but not limited to, prostate cancer, lung cancer, liver cancer, colon cancer, etc.;

[0025] Furthermore, the dehydroabietin amine and squaramide compounds are preferably 1-3.

[0026] Furthermore, the drug is a drug that causes G1 arrest and apoptosis of tumor cells and regulates autophagy of tumor cells;

[0027] The invention discloses a pharmaceutical composition prepared from the dehydroabietin amine and squaramide compounds and conventional pharmaceutical carriers.

[0028] The dehydroabietin amine and squaramide compounds of the present invention can be prepared into various practical medicaments, such as granules, tablets, pills, capsules, injections, suspensions or emulsions, by conventional methods.

[0029] The present invention verifies that the dehydroabietin amine and squaramide compounds have a significant effect of inhibiting the proliferation of different types of tumor cells through in vitro antitumor activity evaluation of the dehydroabietin amine and squaramide compounds and the tumor cell apoptosis activity evaluation induced by the dehydroabietin amine and squaramide compounds, among which the antitumor activity of compound 2 with the best inhibitory effect is significantly better than that of the control drug.

[0030] The present invention evaluates the anti-tumor activity of the dehydroabietinamine and squaramide compound 2 in vivo, and confirms that the compound 2 has obvious activity in inhibiting tumor growth in tumor-bearing mice.

[0031] In view of the simple and easy preparation process of such compounds, the low price of raw materials and the ease of acquisition; the series of compounds can be used to seek their anti-tumor targets through structure-activity relationship research, providing valuable guidance for further drug development. Therefore, the dehydroabietin amine and squaramide compounds of the present invention provide a basis for new drug screening.

[0032] The tumors described in the present invention include but are not limited to prostate cancer, lung cancer, liver cancer, colon cancer, etc.;

[0033] The drug is a drug that induces G1 phase arrest and apoptosis of tumor cells and regulates autophagy of tumor cells;

[0034] The dehydroabietin amine and squaramide compounds include but are not limited to 1-11.

[0035] A dehydroabietin amine and squaramide compound and pharmaceutical composition, characterized in that the dehydroabietin amine and squaramide compound is made of a conventional pharmaceutical carrier and is prepared into various practical medicaments such as granules, tablets, pills, capsules, injections, suspensions or emulsions by conventional methods.

[0036] Beneficial Effects

[0037] Dehydroabietin amine and squaramide derivatives are a new type of biologically active structure. Through in vitro antitumor activity experiments, these compounds all show different degrees of anti-tumor cell proliferation activity, among which compound 2 (R = (1S, 2S)-2-NH2-cyclohexyl) shows the strongest activity. It can effectively inhibit tumor cell growth at low concentrations, induce tumor cells to produce G1 phase arrest, and induce tumor cell apoptosis. In vivo antitumor experimental studies have shown that compound 2 can significantly inhibit tumor growth in tumor-bearing mice. The preparation process of this type of compound is simple and easy, and the raw materials are cheap and easy to obtain; therefore, this type of new dehydroabietin amine and squaramide structure provides a basis for the development of new anti-tumor drugs and has good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 : Detection diagram of compound 2 inducing tumor cell apoptosis;

[0039] Figure 2 : Detection diagram of compound 2 inducing tumor cell cycle arrest;

[0040] Figure 3 : Electron microscopic image of compound 2 inducing autophagy in tumor cells;

[0041] Figure 4 : Compound 2 affects tumor growth in tumor-bearing mice - time-tumor volume and body weight change curve;

[0042] Figure 5 : Box plot of tumor weight and anatomical diagram of solid tumors showing the effect of compound 2 on tumor growth in tumor-bearing mice two weeks later. DETAILED DESCRIPTION

[0043] The following will be combined with the accompanying drawings of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. In addition, in the present invention, the embodiments described below are for better illustrating the present invention and are not intended to limit the scope of the present invention.

[0044] Example 1: Evaluation of the in vitro antitumor activity of compounds

[0045] Test tumor cells: human liver cancer cell HepG2, human lung cancer cell A549, human prostate cancer cell DU145, human colon cancer cell HT29, human colon cancer cell HCT15.

[0046] Cell culture: DMEM, DMEM-F12, MEM, RPMI 1640 and McCoys5A medium, 10% fetal bovine serum and 1% penicillin-streptomycin were used as culture medium. The cultured cell lines were placed at 37°C and 5% CO2 saturated humidity for routine culture and passage. All experiments used cells in the logarithmic growth phase.

[0047] In vitro antitumor activity evaluation (MTT method):

[0048] The above tumor cells were plated on 96-well plates, and after the monolayer was grown in a 37°C, 5% CO2 incubator, the cell culture medium was discarded, and the cell maintenance medium containing different concentrations of the test compound was added to continue the culture. The cells without drug action were used as blank controls. Each group had 8 replicate wells and continued to culture for 48 hours. The cell status was visually observed and recorded under a microscope. 10 μL of MTT (5 mg / mL) was added to each well and continued to culture for 4 hours. The supernatant was discarded, and 100 μL of DMSO was added to each well. The cells were incubated at 37°C for 10 minutes, and the absorbance at a wavelength of 490 or 570 nm was detected by an enzyme marker. The average inhibition rate was calculated according to the following formula:

[0049] Inhibition rate = (average OD value of the control group - average OD value of the drug group) / average OD value of the control group) × 100%.

[0050] The test results showed that the eleven dehydroabietin amine and squaramide compounds prepared showed excellent inhibitory activity against the tested tumor cells and drug-resistant cell lines, and their half inhibitory concentration (IC 50 The specific results are shown in Table 1 below, among which compound 2 has the best anti-tumor effect.

[0051] Table 1 Inhibitory activity of dehydroabietin amine and squaramide compounds on tumor cells (IC 50 )

[0052]

[0053] Example 2: Evaluation of tumor cell apoptosis activity induced by compound 2

[0054] The applicant further implemented an experiment on compound 2 inducing tumor cell apoptosis, and the experimental conditions were as follows: HT29 cells in the logarithmic growth phase were plated on a 6-well plate, and after the monolayer was fully grown, cell maintenance medium containing 2.5 μM, 10 μM, and 15 μM of compound 2 was added for incubation, and a cell control without drug treatment was set. After 24 hours, the cells were collected and apoptosis was detected on a flow cytometer using the Annexin-FITC / PI apoptosis detection kit.

[0055] The experimental results are as follows Figure 1 The results show that 15 μM compound 2 can strongly induce apoptosis of the above tested tumor cells.

[0056] Example 3: Evaluation of G1 activity of tumor cells induced by compound 2

[0057] The applicant further conducted an experiment on compound 2 inducing tumor cell apoptosis. The experimental conditions were as follows: HT29 cells in the logarithmic growth phase were plated in 6-well plates, and after the monolayer was fully grown, cell maintenance medium containing 2.5 μM, 10 μM, and 15 μM compound 2 was added for incubation. A cell control without drug treatment was set up. After 24 hours, the cells were collected and the cell cycle was analyzed on a flow cytometer using PI / RNase staining solution.

[0058] The experimental results are as follows Figure 2 The results show that 2.5 μM, 10 μM, and 15 μM of compound 2 can strongly induce G1 phase arrest in the above-tested tumor cells.

[0059] Example 4: Evaluation of Tumor Cell Autophagy Induced by Compound 2

[0060] The applicant further conducted an experiment on the induction of autophagy in tumor cells by compound 2. The experimental results are as follows: HT29 cells in the logarithmic growth phase were spread over 150 mm 2 After the cell culture dish is full of monolayer cells, add cell maintenance medium containing 5 μM and 10 μM compound 2 for incubation, set up cell control without drug treatment, collect cells after 24 hours, make slices and observe under electron microscope.

[0061] The experimental results are as follows Figure 3 The results showed that 5 μM and 10 μM compound 2 could strongly induce autophagy in HT29 cells.

[0062] Example 5: Evaluation of the in vivo antitumor activity of compound 2

[0063] The applicant further carried out an in vivo anti-tumor activity evaluation of Compound 2. The test results are as follows: the HT29 xenograft tumor nude mouse model was given the drug by oral gavage and intraperitoneal injection for 31 days. The tumor growth was monitored every day. After the last administration, the tumor mass was removed and weighed.

[0064] The experimental results are as follows Figure 4 The results show that, compared with the control group, compound 2 can significantly slow down the tumor growth rate in the HT29 xenograft tumor nude mouse model, showing good in vivo anti-tumor activity.

[0065] In summary, the novel dehydroabietin amine and squaramide compounds have good inhibitory effects on the proliferation of different tumor cells. Compound 2 has shown excellent anti-tumor activity against a variety of tumor cells, especially against colon cancer HT29 cells, showing great application potential. In addition, compound 2 also showed good tumor growth inhibition activity in the xenograft tumor nude mouse model. If further clinical research is carried out, it is expected to be prepared into a drug that is effective against tumor diseases.

Claims

1. Application of dehydroabietin amine and squaramide compounds in the preparation of anti-tumor drugs. The preparation route and structure of the dehydroabietin amine and squaramide compounds are as follows: Where R 1 =2-NH2-cyclohexyl or R 1 =(1S,2S)-2-NH2-cyclohexyl or R 1 =(1R,2R)-2-NH2-cyclohexyl or R 1 =(1R,2R)-N,N-dimethyl-cyclohxyl or R 1 =(1S,2S)-N,N-dimethyl-cyclohexyl The tumors are lung cancer, prostate cancer, liver cancer and colon cancer.

2. Application of dehydroabietin amine and squaramide compounds in the preparation of anti-tumor drugs. The preparation route and structure of the dehydroabietin amine and squaramide compounds are as follows: Where R 2 =3,5-diBr-phenyl or R 2 =3-F-5-CF3-phenyl or R 2 =3-Cl-5CF3-phenyl or R 2 =3-Br-5-CF3-phenyl or R 2 =2-F-4-CF3-phenyl or R 2 =3,5-diCF3-phenyl The tumors are lung cancer, prostate cancer, liver cancer and colon cancer.

3. A pharmaceutical composition comprising the dehydroabietin amine and squaramide compound as claimed in claim 2, characterized in that The pharmaceutical composition is prepared from a dehydroabietin amine and a squaramide compound and a conventional pharmaceutical carrier, and the pharmaceutical composition is prepared into granules, tablets, pills, capsules, injections, suspensions or emulsions by conventional methods; the pharmaceutical composition induces G1 phase arrest and cell apoptosis in tumor cells and regulates autophagy of tumor cells.